Merck KGaA reported a 3% increase in group revenues in the third quarter, to €1.94 billion, with strong growth in sales of the multiple sclerosis drug Rebif (interferon beta-1a) and the anticancer Erbitux (cetuximab) bolstering the figure.
Sales in the company's pharma business, Merck Serono, rose by 6% to €1.31 billion. However, high costs for late-stage clinical...
Welcome to Scrip
Create an account to read this article
Already a subscriber?